aspartic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1550 56-84-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • L-Aspartic acid
  • asparagic acid
  • aspartic acid
One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
  • Molecular weight: 133.10
  • Formula: C4H7NO4
  • CLOGP: -2.41
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 3
  • TPSA: 100.62
  • ALOGS: 0.03
  • ROTB: 3

Drug dosage:

None

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 643.97 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypokalemia indication 43339004
Hypokalemia Prevention indication
Hyperkalemia contraindication 14140009
Complete atrioventricular block contraindication 27885002
Gastrointestinal ulcer contraindication 40845000
Congenital myotonia, autosomal dominant form contraindication 57938005
Acute nephropathy contraindication 58574008
Diarrhea contraindication 62315008
Kidney disease contraindication 90708001 DOID:557
Gastrointestinal obstruction contraindication 126765001
Gastroparesis contraindication 235675006
Chronic diarrhea contraindication 236071009
Hyporeninemic hypoaldosteronism contraindication 236464008
Familial hyperkalemic periodic paralysis contraindication 304737009 DOID:14451
Severe dehydration contraindication 450316000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.45 acidic
pKa2 3.18 acidic
pKa3 10.47 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Aspartate--tRNA ligase, cytoplasmic Enzyme WOMBAT-PK
Aspartyl/asparaginyl beta-hydroxylase Enzyme WOMBAT-PK
Aspartate aminotransferase, mitochondrial Enzyme WOMBAT-PK
Aminoacylase-1 Enzyme WOMBAT-PK
Argininosuccinate synthase Enzyme WOMBAT-PK
Asparagine synthetase [glutamine-hydrolyzing] Enzyme WOMBAT-PK
Aspartoacylase Enzyme WOMBAT-PK
Aspartate aminotransferase, cytoplasmic Enzyme WOMBAT-PK
Calcium-binding mitochondrial carrier protein Aralar1 Unclassified WOMBAT-PK
Calcium-binding mitochondrial carrier protein Aralar2 Unclassified WOMBAT-PK
Glutamate NMDA receptor Ion channel IC50 5.79 CHEMBL

External reference:

IDSource
D001224 MESH_DESCRIPTOR_UI
4018680 VUID
N0000146991 NUI
C0004015 UMLSCUI
D00013 KEGG_DRUG
30KYC7MIAI UNII
1570 INN_ID
4018680 VANDF
NOCODE MMSL
44970006 SNOMEDCT_US
1169 RXNORM
000933 NDDF
5960 PUBCHEM_CID
CHEBI:22660 CHEBI
CHEMBL274323 ChEMBL_ID
DB00128 DRUGBANK_ID
IAS PDB_CHEM_ID
3309 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3200 SOLUTION 434 mg INTRAVENOUS ANDA 13 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-3205 SOLUTION 434 mg INTRAVENOUS ANDA 13 sections
Plenamine HUMAN PRESCRIPTION DRUG LABEL 17 0264-4500 SOLUTION 434 mg INTRAVENOUS ANDA 13 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9341 SOLUTION 0.32 g INTRAVENOUS NDA 12 sections
TrophAmine HUMAN PRESCRIPTION DRUG LABEL 20 0264-9361 SOLUTION 0.19 g INTRAVENOUS NDA 12 sections
ProSol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0499 INJECTION, SOLUTION 600 mg INTRAVENOUS NDA 15 sections
Clinisol HUMAN PRESCRIPTION DRUG LABEL 17 0338-0502 INJECTION, SOLUTION 434 mg INTRAVENOUS ANDA 11 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1130 INJECTION, SOLUTION 0.32 g INTRAVENOUS ANDA 12 sections
Premasol - sulfite-free (Amino Acid) HUMAN PRESCRIPTION DRUG LABEL 19 0338-1131 INJECTION, SOLUTION 0.19 g INTRAVENOUS ANDA 12 sections
Aminosyn-PF HUMAN PRESCRIPTION DRUG LABEL 18 0409-4178 INJECTION, SOLUTION 370 mg INTRAVENOUS NDA 12 sections
Aminosyn-PF HUMAN PRESCRIPTION DRUG LABEL 18 0409-4179 INJECTION, SOLUTION 527 mg INTRAVENOUS NDA 12 sections
Aminosyn II HUMAN PRESCRIPTION DRUG LABEL 17 0409-7171 INJECTION, SOLUTION 1050 mg INTRAVENOUS NDA 13 sections
Aminosyn II HUMAN PRESCRIPTION DRUG LABEL 17 0409-7172 INJECTION, SOLUTION 700 mg INTRAVENOUS NDA 13 sections
Aminosyn-PF HUMAN PRESCRIPTION DRUG LABEL 18 0990-4179 INJECTION, SOLUTION 527 mg INTRAVENOUS NDA 12 sections
Aminosyn II HUMAN PRESCRIPTION DRUG LABEL 17 0990-7171 INJECTION, SOLUTION 1050 mg INTRAVENOUS NDA 13 sections
Aminosyn II HUMAN PRESCRIPTION DRUG LABEL 17 0990-7172 INJECTION, SOLUTION 700 mg INTRAVENOUS NDA 13 sections
Kabiven HUMAN PRESCRIPTION DRUG LABEL 22 63323-712 INJECTION, EMULSION 99 mg INTRAVENOUS NDA 18 sections
Perikabiven HUMAN PRESCRIPTION DRUG LABEL 22 63323-714 INJECTION, EMULSION 71 mg INTRAVENOUS NDA 18 sections